Search

Your search for "SIGY" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare

April 12, 2024

Sigyn Therapeutics (OTCQB: SIGY), a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare. “As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through […]

News Articles

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

April 1, 2024

Sigyn Therapeutics (OTCQB: SIGY), a San Diego-headquartered medical technology company that creates medical solutions to treat life-threatening conditions, took part in the recent Emerging Growth Conference, with CEO Jim Joyce giving a live online presentation and updating attendees on the company’s portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM), which have each been […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

March 27, 2024

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges

March 20, 2024

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

March 15, 2024

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

March 5, 2024

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification […]

News Articles

Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare

March 5, 2024

Medical technology company Sigyn Therapeutics (OTCQB: SIGY) is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. The company has a proven team of professionals with multiple first-in-industry achievements. The company’s lead […]

News Articles

Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023

February 27, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released its year-end 2023 financials and additionally disclosed the completion of a 1-for-40 reverse split of its common stock was implemented on January 31, 2024. As a result of this split, Sigyn’s common stock will trade under the ticker symbol “SIGYD” for 20 business […]

News Articles

Sigyn Therapeutics Inc. (SIGYD) CEO Discusses Opportunities to Treat Cancer and Drug-Resistant Pathogens in Letter to Shareholders

February 23, 2024

James A. Joyce, the Chairman and CEO of development-stage medical technology company Sigyn Therapeutics (OTCQB: SIGYD, SIGY), recently discussed the company’s opportunities, challenges, and decision-making processes in a letter to shareholders (https://ibn.fm/wGTqS). The company is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health: Sigyn Therapeutics designed […]

News Articles

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

February 21, 2024

Sigyn Therapeutics (OTCQB: SIGYD, SIGY), a development-stage medical technology company creates therapeutic candidates with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in global health, and 2) their successful clinical advancement would provide a potential competitive advantage within an established therapeutic industry segment. The company’s therapeutic candidates include: Sigyn […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

February 2, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business […]

InvestorNewsBreaks

InvestorNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

January 24, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, […]

News Articles

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

January 8, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy(TM) to address pathogen-associated inflammatory disorders, the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep(TM) to improve the delivery of cancer chemotherapy and ChemoPure(TM) to reduce the toxicity of chemotherapy. Sigyn […]

InvestorNewsBreaks

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes

January 4, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released a shareholder letter from chair and CEO Jim Joyce. In the letter, whose objective is to help shareholders better understand SIGY opportunities, challenges and decision-making processes, Joyce reiterates the company’s long-term objective of building an enduring organization whose therapies save lives. The letter […]

News Articles

SideChannel Inc. (SDCH) Ability To Make Powerful Cybersecurity Accessible For Small and Mid-sized Companies Results In 64% to 71% Year-Over-Year Revenue Increase

December 8, 2022

With a mission to make cybersecurity simple and accessible, SideChannel’s (OTCQB: SDCH) belief is that small and mid-sized organizations deserve the expertise of an experienced CISO (Chief Information Security Officer), just as much as a larger enterprise but at a more reasonable cost. The company is helping organizations all over the world improve their cybersecurity […]

News Articles

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

November 15, 2021

 Virtual:  November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences.  Over 90 presenting companies from a wide spectrum […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).